Canaccord initiated coverage of Tango Therapeutics (TNGX) with a Buy rating and $30 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics price target raised to $21 from $14 at B. Riley
- Tango Therapeutics price target raised to $20 from $19 at Mizuho
- Tango Therapeutics price target raised to $24 from $15 at Stifel
- Tango Therapeutics price target raised to $19 from $15 at Wedbush
- Tango Therapeutics price target raised to $20 from $18 at Guggenheim